BIIB•benzinga•
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
Summary
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 19, 2025 by benzinga